Bococizumab

Modify Date: 2024-04-06 01:19:06

Bococizumab Structure
Bococizumab structure
Common Name Bococizumab
CAS Number 1407495-02-6 Molecular Weight N/A
Density N/A Boiling Point N/A
Molecular Formula N/A Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Bococizumab


Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].

 Names

Name Bococizumab

 Bococizumab Biological Activity

Description Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].
Related Catalog
Target

PCSK9[1]

In Vivo Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development[2]. Animal Model: Pregnant Sprague-Dawley (SD) rats[1] Dosage: 0, 10, 30, and 100 mg/kg Administration: Intravenous injection (i.v.) Result: Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters.
References

[1]. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505.

[2]. Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70.

 Chemical & Physical Properties

No Any Chemical & Physical Properties